These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31976778)

  • 1. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.
    Balyan R; Hahn D; Huang H; Chidambaran V
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):125-141. PubMed ID: 31976778
    [No Abstract]   [Full Text] [Related]  

  • 2. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.
    Kibaly C; Alderete JA; Liu SH; Nasef HS; Law PY; Evans CJ; Cahill CM
    Cell Mol Neurobiol; 2021 Jul; 41(5):899-926. PubMed ID: 33245509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective.
    Gadd S; Cox N; Samuelson J; Kenney A; Turner K; Cochran G
    Ther Drug Monit; 2021 Feb; 43(1):35-41. PubMed ID: 33278243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.
    Brushwood DB; Rich BA; Coleman JJ; Bolen J; Wong W
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):333-48. PubMed ID: 21133741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
    Cohen JP; Mendoza M; Roland C
    Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of prodrug technology and its application for developing abuse-deterrent opioids.
    Gudin JA; Nalamachu SR
    Postgrad Med; 2016 Jan; 128(1):97-105. PubMed ID: 26615852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid Use and Overdose: What We've Learned in Ontario.
    Gomes T; Juurlink DN
    Healthc Q; 2016; 18(4):8-11. PubMed ID: 27009700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse-deterrent Opioid Formulations.
    Litman RS; Pagán OH; Cicero TJ
    Anesthesiology; 2018 May; 128(5):1015-1026. PubMed ID: 29252508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.